Drug Trial Radar · NCT07114315
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Sep 19, 2025
Primary completion
Aug 2027
Study completion Aug 2028
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Aug 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center phase II clinical study consisting of two parts: Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer. Part II: To evaluate the safety and efficacy of AK112, either as monotherapy or in combination with AK130, in advanced pancreatic cancer.
Conditions
- Pancreatic Cancer
Interventions
AK112Drug
Following a predefined dose and date.
AK130Drug
Following a predefined dose and date.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with adverse events (AEs)Time frame: From the time of informed consent signed through 30 days after the last dose of study drug or starting new anti-cancer therapy.
- Objective Response Rate (ORR)Time frame: Through study completion, an average of 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.